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HERV-H sequences comprise a large family of human endogenous retrovirus-like elements. Previous DNA sequence
comparisons of HERV-H long terminal repeats (LTRs) have led to their classification into three subtypes, Types I, Ia, and
II. Type Ia appears to have been generated by recombination between Type I and Type II LTRs. These subtypes differ in
evolutionary age and transcriptional activity with Type Ia LTRs being younger in evolutionary terms and possessing stronger
promoter function than the other two subtypes. In this study, possible mechanisms responsible for the functional difference
between LTRs have been explored. Types I and II LTRs each contain different sets of repeated segments in their U3 regions
which are disrupted in Type Ia LTRs. Using reporter gene assays, we have shown that both types of repeated segments
can suppress activity of the human b-globin gene promoter when cloned at a distant site. Both sets of repeats also repress
promoter activity of a Type Ia LTR when directly inserted within its U3 region. In addition, using deletion constructs, we
have localized two positive regulatory segments within the Type Ia LTR, both of which contain a potential binding site for
the transcription factor Sp1. Gel mobility shift assays demonstrated that fragments containing these sites do bind Sp1.
Although Type I LTRs are generally similar to Type Ia LTRs in the regions surrounding the Sp1 sites, there are sequence
differences within the sites. Gel-shift analysis revealed no or much reduced Sp1 binding of Type I LTR fragments containing
these sites. Thus, it appears that the loss of repeated suppresser elements and the acquisition of Sp1-binding sites have
both contributed to the relatively strong transcriptional activity of the Type Ia LTRs. q 1996 Academic Press, Inc.
Many families of human retrovirus-like elements, between a Type I and a Type II LTR (6). HERV-H elements
with Type I or II LTRs are more numerous and oldertermed HERVs, have been described and range in copy
than elements with Type Ia LTRs, indicating that Type Ianumber from 1 to 1000 members per haploid genome
elements represent a more recently expanded subpopu-(for reviews see 1, 2). The HERV family with the greatest
lation (6). Interestingly, Type Ia LTRs are expressed en-number of full elements, as opposed to solitary long ter-
dogenously in the widest range of cell lines and areminal repeats (LTRs), is the HERV-H (or RTVL-H) family
also the strongest promoters when tested individually inwhich contains approximately 1000 members and close
reporter gene assays (6, 7).to 1000 solitary LTRs found on all chromosomes (3, 4).
The structural and functional differences between LTRWe have been interested in analyzing the transcriptional
types have led us to hypothesize that the types I and IIregulatory sequences within the LTRs of HERV-H ele-
repeat units may be associated with a suppressor func-ments since their abundance in the genome suggests
tion and that the disruption of these repeat units in Typethat they could alter the expression of nearby genes.
Ia LTRs contributes to their promoter strength. As anHERV-H LTRs can be classified into three main subtypes,
initial test of this hypothesis, we cloned a set of type ITypes I, Ia, and II, based on different repeated segments
repeats or a set of type II repeats as shown in Fig. 1Ain their U3 regions (5, 6). Type I LTRs contain two or
into the distant XbaI site of pSVABGCAT(X) (8, 9), whichthree copies of a 49- to 52-bp ‘‘type I’’ repeat, whereas
has the human b-globin gene promoter driving the chlor-Type II LTRs contain only one type I repeat followed by
amphenicol acetyltransferase (CAT) gene. In most cells,four to six copies of a 27- to 34-bp ‘‘type II’’ repeat (Fig.
this promoter is enhancer dependent (8) but it does have1A). Type Ia LTRs have a single type I repeat followed
some activity without an added enhancer in the humanby a single type II repeat. Sequence comparisons sug-
adenovirus-transformed embryonal kidney cell line 293gest that the Type Ia LTR arose via a recombination event
(unpublished observations). Therefore, both potential en-
hancer or repressor activity of DNA segments inserted1 To whom correspondence and reprint requests should be ad-
into the XbaI site can be measured using this vector indressed at Terry Fox Laboratory, B.C. Cancer Agency, 601 West 10th
293 cells. Plasmids were transfected using the calciumAvenue, Vancouver, B.C. V5Z 1L3. Fax: (604) 877-0712; E-mail: dixie@un-
ixg.ubc.ca. phosphate method (10) and CAT assays were performed
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FIG. 1. (A) Sequences of the PCR-amplified repeat regions from Type I and Type II LTRs. Type I repeats were amplified from the RTVL-H2 5* LTR (11)
and type II repeats from the cPj LTR (12). Sequences of primers used are available upon request and PCRs used standard conditions (13). Lowercase
letters indicate mismatch bases in primers creating the XbaI site. Bold sequences are the repeats themselves stacked sequentially to show matching
bases. Type I repeat consensus sequence is composed of bases maintained in both copies shown and type II repeat consensus sequence is composed
of bases maintained in at least four of six type II repeats shown. Numbering is from the beginning of each LTR. (B) Summary of CAT assays testing the
effect of the LTR repeats on the b-globin promoter in 293 cells. Data from four experiments was pooled by using BGX [pSVABGCAT(X)] as an internal
control and setting its conversion level to one for each round of transfections. Test constructs were BGT1 and BGT2, containing one set of the type I
and type II repeats, respectively, and BGT1X2a and b, independent clones each containing two copies of the type I repeat set (four repeat units). The
positive control, BGLR [pSVABGCAT(LR)], has the SV40 enhancer cloned at the same site (8, 9). Results were quantified by scintillation counting and are
given relative to BGX. Gray error bars indicate sample standard deviation. (C) Summary of CAT assays testing the effect in NTera2D1 cells of inserting
the LTR repeats into a Type Ia LTR. H6 [pSVAH6fCAT(X)] is the original H6 Type Ia LTR driving the CAT gene (7). Both type I and type II repeat regions
and a size-matched 210-bp HinfI fragment of pUC19 DNA were cloned into an internal NcoI site of the H6 LTR to make H6-T1, H6-T2, and H6-210,
respectively. N10-14 is the same CAT vector with the N10-14 Type I LTR cloned in place of the H6 LTR (7). Data from four experiments were pooled
using the conversion level of the parent construct H6 set to 1 for each round of transfection.
48 hr later as described previously (7) on equal amounts in the construct BGT1, had only a slight negative effect
on b-globin promoter activity. However, the promoter ac-of protein from cell extracts. The results of multiple exper-
iments are shown in Fig. 1B. One set of type I repeats, tivity of two independent constructs, BGT1X2a and -b,
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each containing two sets (four copies) of type I repeats, bp 5* to the DraII site results in only a small change in
promoter activity. However, deletion of the next 32 bp 5* towas significantly reduced. The naturally occurring 6-unit
type II repeat set in the construct BGT2 reduced reporter the NcoI site caused a threefold decrease in activity. This
32-bp region contains the potential binding site for Sp1 atoutput by approximately one-half. These results suggest
that the repeat regions can have a suppressing effect on position 115. Deletion of the next 91 bp between the NcoI
and DraIII sites causes only a slight further decrease ina distant cellular promoter.
To test more directly if the lack of intact repeat regions activity but removal/alteration of the next 15 bp including
the second potential Sp1 site results in a further reductionin the Type Ia LTR contributes to its strong promoter
activity, we cloned the same types I and II repeat regions, of approximately fourfold to 4.3% of control.
We next determined if Sp1 does bind sequences in theof 171 and 262 bp, respectively, into the Type Ia LTR,
termed H6, at an NcoI site found within its single type II Type Ia LTR and whether there is a difference in Sp1
binding to analogous regions in the Type I LTR. To dorepeat (6, 7). This position is analogous to the native
location of the repeat sets in other LTRs. These recombi- this, restriction fragments were isolated from the Type Ia
H6 LTR and the Type I N10-14 LTR and used in gel mobilitynant LTRs were then tested directly for promoter activity
in the human teratocarcinoma cell line NTera2D1 (14) shift assays in the presence of purified Sp1 protein. The
fragments used are shown in Fig. 3. The H100 fragmentusing CAT vectors. Promoter activity of the Type I LTR
N10-14 was also measured in this system for compari- from the H6 LTR contains the first putative Sp1 site at
position 115. The N113 fragment contains the analogousson. Results are shown in Fig. 1C normalized to the activ-
ity of the native H6 LTR. Insertion of the type I repeat region in the N10-14 LTR. Comparison of these two seg-
ments in Fig. 3 shows that the N10-14 LTR has an Aregion (H6-T1) suppressed activity of the H6 LTR to 0.29
of control and the type II repeat region (H6-T2) reduced instead of a G within the CGCC core of the potential Sp1
site. The H145 fragment from the H6 LTR contains theactivity to 0.20 of control. This decrease in activity was
not simply due to an effect of lengthening the LTR since second putative Sp1 site at position 237 and the analo-
gous region in N10-14 is contained on the N153 fragment.no drop occurred when a fragment from pUC19 was in-
serted to make the construct H6-210. In this case, the While the two LTRs are quite similar in the region encom-
passed by the H145 and N153 fragments, there are sev-average activity was somewhat higher than H6 but the
sample standard deviation was also high, resulting in no eral nucleotide differences within the putative Sp1 sites
(Fig. 3). Figures 3A and 3B compare the ability of the H100statistically significant difference in promoter activity.
The above experiments show that the presence of sets and N113 fragments to bind Sp1. H100 does specifically
associate with Sp1, whereas there was no detectable Sp1of type I or II repeats within a Type Ia LTR is associated
with a reduced promoter activity. However, insertion of binding to the N113 fragment. Figures 3C and 3D compare
binding of the H145 and N153 fragments. The H145 frag-these repeat regions does not suppress activity to a level
comparable to Type I or II LTRs. In a previous study, the ment bound Sp1 and this association was even stronger
than that observed for the H100 fragment. The N153 frag-Type I LTR N10-14 was found to be the strongest promoter
among all Types I and II LTRs examined (7). However, Fig. ment also associated with Sp1 but relatively weakly. Even
this weak association was at first surprising since the Sp11C shows that promoter activity of the N10-14 Type I LTR
is still significantly below that of the Type Ia LTR H6 with site at position 237 in the H6 LTR is quite disrupted in the
N10-14 LTR. However, closer examination of the sequencethe repeat regions inserted. This finding indicates that lack
of an intact block of type I or II repeats is not solely respon- revealed another possible Sp1 site in N10-14 located 15
bp downstream (underlined in Fig. 3) that could be respon-sible for the strong promoter function of Type Ia LTRs.
Previously, it had been suggested that the acquisition of sible for the weak Sp1 binding. These results indicate that
the Type Ia LTR H6 contains at least two strong bindingbinding sites for the transcription factor Sp1 may have con-
tributed to the promoter strength of Type Ia LTRs (7). Se- sites for Sp1 that are lacking in the Type I LTR N10-14.
Sp1 binding sites have also been shown to be im-quence comparisons between the H6 Type Ia LTR and
other LTRs identified a unique potential Sp1-binding site at portant in the differences in behavior observed in Molo-
ney leukemia (MuLV)-related retroviruses. MuLV is notposition 237 (underlined in Fig. 2A). A similar CG-rich site
is present at position 115. To investigate the importance able to productively infect embryonic stem (ES) cells or
embryonal carcinoma (EC) cells. One of the mutations inof these regions and to localize other potential positive
regulatory regions in the Type Ia LTR, a series of 5* dele- the derivative myeloproliferative sarcoma virus creates
an Sp1-binding site not present in MuLV which is respon-tions was constructed using the restriction enzyme sites
shown in Fig. 2A. One final deletion construct, termed sible for the expansion of host cell range to both ES and
EC cells (15, 16). An Sp1 site has also been found in theSp1(0), was constructed by PCR using the Sp1 minus and
LTRpolyA primers indicated in Fig. 2A. This deletion short- LTRs of the ERV9 family of human endogenous retrovi-
ruses which is expressed in undifferentiated teratocarci-ened the DraIII construct by 15 bp thus removing the poten-
tial Sp1-binding site at position 237. These deleted forms noma or EC cells (17). Interestingly, after this manuscript
was submitted, it was reported that some HERV-H Typewere then tested for promoter activity in NTera2D1 cells
and results are shown in Fig. 2B. Deletion of the first 104 I LTRs bind Sp1 at a site just 3 * to the TATA box (18), a
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FIG. 2. (A) Sequence of the portion of the H6 Type Ia LTR used to test promoter function (7). Restriction sites shown are those used in the
construction of serial 5* deletions. Putative Sp1-binding sites are underlined and the TATA box is indicated. The PCR primers Sp1 minus and
LTRpolyA, used to create the Sp1-deletion construct, are shown below the sequence. Lowercase letters in the primers indicate a HindIII site used
for cloning. (B) Summary of the relative promoter activities of the deletion constructs in NTera2D1 cells. Constructs are all named for the restriction
sites used in their 5* truncation except Sp1(0) which was constructed using PCR. The striped box is a 52-bp type I repeat unit, the light gray box
is a 30-bp type II repeat unit and the dark gray box represents a 100-bp section common to Type I and Ia elements not found in Type II LTRs.
All unshaded regions show sequences relatively conserved between LTR types. Triangles locate the putative Sp1 sites and the boxed T indicates
the TATA box. CAT assay data were pooled using the H6 construct as an internal control with activity set at 100% for each of five rounds of
transfections.
region not analyzed in this study. However, sequence we have tested a cH-4 5* LTR fragment with this site in
a gel-shift assay and found that its binding to Sp1 wascomparisons in this region of Type I and Ia LTRs show
no differences, suggesting that differential Sp1 binding comparable to that of the H6 fragment (data not shown).
Type I LTRs from 12 elements are available for compari-at this downstream site does not contribute to the differ-
ences in functional capacities of these LTRs. son. At the first site, approximately half the Type I LTRs
are identical to N10-14. The other half are different fromThere are approximately 100 Type Ia LTRs and several
hundred Type I LTRs per haploid genome (6). To ascer- both N10-14 and the Type Ia site and it is unknown
whether the site in these LTRs binds Sp1. At the secondtain if the difference in Sp1 binding between H6 and N10-
14 may be typical of the entire population of Type Ia and site, all the Type I LTRs have sequences identical or very
similar to N10-14 with all having an A in place of theType I LTRs, we compared the segments spanning the
two H6 Sp1 sites in all LTRs that have been sequenced. critical G in the core of the site. Thus, at least with regard
to the second site, our findings with H6 and N10-14 areIn the case of Type Ia LTRs, only 1 other HERV-H element,
termed cH-4, with Type Ia LTRs has been isolated (6). most probably indicative of the Type I and Ia LTR subsets
as a whole. The possible weak Sp1 site in N10-14 locatedBoth the 5* and the 3 * LTRs of this element are identical
to the H6 LTR at the first Sp1 site. At the second site, downstream of the second site is not found in any other
Type I LTR that has been analyzed. That is, all havethe cH-4 5* LTR has TGCC in place of CGCC. However,
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FIG. 3. Autoradiographs of gel mobility shift assays using restriction fragments derived from the H6 Type Ia LTR: (A) H100 and (C) H145; and the N10-
14 Type I LTR: (B) N113 and (D) N153. Sequence comparison of the H100 and N113 fragments is shown below A and B and comparison of the H145
and N153 fragments is shown below C and D. Sp1 is 0.5 fpu purified human protein; (/) indicates inclusion and (0) indicates exclusion in the reaction.
Binding reactions contained 12.5% glycerol, 12 mM HEPES, pH 7.9, 4 mM Tris–HCl, 60 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mg poly(dIrdC), 0.05% NP-
40, and 1 mg bovine serum albumin. Cold competitor is a double-stranded oligonucleotide containing an Sp1-consensus-binding site (Promega). Amount
of competitor is given as amount molar excess. Sp1 protein (Promega) was added to each reaction on ice and incubated for 5 min before 10 fmols of
32P-end-labeled test fragment was added and incubated for 30 min. Reactions were run on a 4% polyacrylamide gel in 0.251 TBE running buffer. Gels
were vacuum dried and exposed to X-ray film. All band intensities were quantified by densitometer scans of each lane.
a string of Cs as opposed to CCGCC found in N10-14 and endogenous retroviral LTRs. Examples include the
LTR of MuLV (19), MuLV-related endogenous LTRs (20),(underlined in Fig. 3). This finding may explain why the
N10-14 LTR is the strongest promoter among the Type I mouse mammary tumor virus LTR (21), and the LTRs of
human T-cell lymphotropic virus (22) and human immu-LTRs that we have tested (7).
The evidence presented here suggests that the re- nodeficiency virus (reviewed in 23). A variety of cellular
genes are also controlled in part by negative repressorpeat structures found within Type I and Type II HERV-
H LTRs contain negative regulatory elements (NREs). elements (24). With regard to endogenous retroviruses
or other mobile genetic elements, the existence of hostNREs have been identified in a number of exogenous
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